Last updated: February 24, 2026
What is NDC 42291-0775?
NDC 42291-0775 refers to Repatha (evolocumab), a PCSK9 inhibitor manufactured by Amgen. Approved by the FDA in August 2015, it is indicated for hyperlipidemia and familial hypercholesterolemia.
Market Landscape
Market Size and Demand Drivers
Repatha operates in the lipid-lowering therapy market, which is driven by the prevalence of cardiovascular disease (CVD). Globally, CVD causes an estimated 17.9 million deaths annually, increasing demand for effective lipid management therapies [1].
In the U.S., the statin market faces challenges due to patient intolerance and residual risk. PCSK9 inhibitors like Repatha address these gaps, particularly in high-risk patients unable to tolerate high-dose statins or those with familial hypercholesterolemia.
Market Penetration and Competition
Repatha's primary competitors include:
- Praluent (alirocumab) by Regeneron
- Inclisiran (Leqvio) by Novartis
Despite early market entry, Repatha's adoption has faced barriers:
- High cost per dose (~$5,850 for 420 mg annually, per Medicare [2])
- Limited awareness or prescribing inertia
- Insurance and pricing restrictions
However, recent labels expand indications to include homozygous familial hypercholesterolemia (HoFH) and a broader patient population, increasing potential demand.
Market Trends and Projections
In 2022, the global PCSK9 inhibitor market was valued at approximately USD 13 billion, with an expected compound annual growth rate (CAGR) of 7-10% over the next five years [3].
The U.S. market is anticipated to grow at a CAGR of about 8%, reaching USD 16-17 billion by 2027, driven by broader coverage and increased utilization.
Price Projection Analysis
Current Pricing Landscape
Repatha's list price is approximately:
- $5,850 per year for the 420 mg dose (3 injections of 140 mg each)
- Patients with commercial insurance pay roughly $2,300–$3,000 annually after negotiations
- Medicare Part D beneficiaries pay around $75–$100 monthly after subsidies
Factors Influencing Price Trends
- Market competition: Praluent's lower price point may pressure Repatha to reduce prices.
- Biosimilar development: As biosimilars emerge, prices could decrease by 20-40% over the next 3-5 years.
- Patent status: Repatha's key patents expire in 2028-2029, opening pathways for biosimilar entry.
- Pricing reforms: Policy efforts to reduce drug costs, including value-based pricing models, could impact prices.
Future Price Projections
Assuming increased biosimilar competition, Repatha's price could decline:
| Year |
Estimated Price Range (per year) |
Notes |
| 2023 |
USD 4,200 – 5,500 |
Current pricing; negotiations ongoing |
| 2025 |
USD 3,800 – 4,800 |
Biosimilar entries, price competition |
| 2027 |
USD 3,000 – 4,000 |
Wider biosimilar coverage, policy impacts |
| 2029 |
USD 2,500 – 3,500 |
Patent expiration, biosimilar prevalence |
Impact of Healthcare Policy and Payer Dynamics
- Value-based contracts may shift Repatha pricing downward.
- Expanded coverage under Medicare and private insurers may incentivize price reductions.
- Payment reform initiatives could further influence net prices.
Summary
Repatha faces market growth driven by rising cardiovascular disease prevalence and evolving indications. Competition and biosimilar entry are expected to exert downward pressure on prices, with a potential reduction of 30-50% over the next five years. Pricing strategies will depend heavily on payer negotiations, regulatory developments, and biosimilar market dynamics.
Key Takeaways
- The cardiovascular market supports steady demand growth for PCSK9 inhibitors.
- Repatha's current list price is around $5,850 annually; net prices are lower due to negotiations.
- Biosimilar competition, patent expiration, and policy reforms will likely reduce prices by 30-50% within five years.
- Overall market value is projected to grow at approximately 8% CAGR through 2027, despite price pressures.
- Market entry barriers include high costs, limited prescriber adoption, and insurance restrictions.
FAQs
Q1: When will biosimilars for Repatha become available?
A1: Biosimilars are likely to enter the U.S. market around 2028-2029, coinciding with patent expirations.
Q2: How does Repatha compare to other lipid-lowering agents in price?
A2: Repatha's current annual cost is around $5,850, higher than generic statins but justified for high-risk or statin-intolerant patients.
Q3: What factors could accelerate price reductions for Repatha?
A3: Biosimilar approvals, policy reforms favoring price competition, and increased market penetration.
Q4: How significant is the impact of payer negotiations on Repatha’s net price?
A4: Payer negotiations can reduce net prices by approximately 35-50%, depending on formulary positioning and contracts.
Q5: What is the growth outlook for the PCSK9 inhibitor market?
A5: The market is expected to grow at a CAGR of 7-10% annually, reaching USD 16-17 billion by 2027.
References
-
World Health Organization. (2021). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
-
Centers for Medicare & Medicaid Services. (2022). Part D Drug Price Data. https://www.cms.gov
-
Grand View Research. (2023). PCSK9 Inhibitors Market Size, Share & Trends. https://www.grandviewresearch.com
